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N
onalcoholic fatty liver disease (NAFLD) is a
global epidemic.(1) Worldwide, 1 in 4 people
have NAFLD.(2) Further, increasing in par-
allel with the rising prevalence of obesity and metabolic
syndrome, the prevalence and public health impact of
NAFLD will worsen.(3) In the coming post–hepatitis
C era, NAFLD will be the hepatologist’s greatest foe;
NAFLD is the fastest-growing cause of cirrhosis and
hepatocellular carcinoma.(3) At the same time, as is
well known, the presence of NAFLD is inextricably
linked to cardiovascular risk.(4,5) Indeed, for patients
with NAFLD, cardiovascular complications may prove
more common and impactful than liver-related mor-
bidity. Associations between NAFLD and cardiovas-
cular risk, however, have been established with
observational data that do not have the power to dis-
cern causality or to disentangle cross-sectional from
longitudinal effects. Study design matters. At present,
the relationship between NAFLD and cardiovascular
risk represents a classic chicken-versus-egg problem.
Data are needed to clarify the temporal interaction
between NAFLD, advanced liver disease, and cardio-
vascular risk. Such an understanding will guide both
the focal points of preventive efforts and the structure
of our collaborative relationship with colleagues in pri-
mary care, endocrinology, and cardiology for patients
at various stages of NAFLD. To this end, Allen and
her colleagues present the new data to date from 3,869
patients with NAFLD defined by diagnosis codes with
careful exclusion of patients with any codes consistent
with viral hepatitis, alcohol use disorder, and other
liver diseases, matched to 15,209 controls included in
the Rochester Epidemiology Project database (1997-
2014).(6) At first glance, like all retrospective observa-
tional cohort studies, any conclusions are intrinsically
limited by selection and information biases. In this
case, however, each variable used data that integrate
not only billing codes but also laboratory values (e.g.,
FIB-4, hemoglobin A1C) and medication use (e.g.,
antihypertensives, insulin secretagogues). These fea-
tures enhance the accuracy of exposure and outcome
ascertainment substantially. By combining longitudi-
nal, population-based data with rigorously defined
comorbidities, these data raise the bar for epidemiolog-
ical associations and provide a better picture of how
NAFLD and comorbidities fit into a sequence.
This study advances the epidemiology of NAFLD
in two principal ways. First, the study suggests that
NAFLD may be an accelerant for cardiovascular risk.
The authors confirm that NAFLD is associated with
increased overall mortality but that this risk is driven
by the burden of metabolic comorbidities. However, in
patients with limited or no metabolic comorbidities,
NAFLD is significantly associated with death and the
Abbreviation: NAFLD, nonalcoholic fatty liver disease.
Received November 13, 2017; accepted November 20, 2017.
Supported in part by the National Institutes of Health (R01-
DK106419-03, to R.L.) and by the National Institute of Environ-
mental Health Sciences of the National Institutes of Health
(P42ES010337). The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institutes of Health.
Copyright VC 2017 by the American Association for the Study of
Liver Diseases.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.29722
Potential conflict of interest: Nothing to report.
ADDRESS CORRESPONDENCE AND
REPRINT REQUESTS TO:
Rohit Loomba, M.D., M.H.Sc.
Altman Clinical and Translational Research Institute
1W202, 9452 Medical Center Drive




HEPATOLOGY, VOL. 67, NO. 5, 2018
A
HE STUDY OF LIVER D I S E ASEST
MERICAN ASSOCIATION FOR
development of new comorbidities. Although all
patients are more likely to advance through the states
of metabolic comorbidity as they age, they show that
NAFLD decreases the “time-in-state” spent by
afflicted patients with lower stages of metabolic comor-
bidity. As comorbidities accrue, the independent effect
of NAFLD on mortality declines. Notably, these asso-
ciations hold when stratified by the presence of cirrho-
sis. This multistate transition model is helping in
assessing the impact of cardiovascular comorbidities on
the mortality associated with NAFLD.
Second, the incidence of NAFLD has risen a stag-
gering 6-fold in less than 20 years. Portending worse
outcomes to come, these trends are most acute for
adults aged 18-39. Retrospective cohort studies are at
risk for confounding by trends in clinical practice that
may lead to increased detection (e.g., more ultra-
sounds) or increased awareness and resultant case find-
ing. Importantly, the authors show that the increasing
NAFLD incidence was distinct from steady rates of
abdominal ultrasound use. The average body mass
index of patients with incident NAFLD rose from
1999 to 2005. This could indicate clinicians actively
ordering or interpreting liver enzyme or ultrasound
results in the context of increasing awareness of
NAFLD in obese patients owing to practice standards
modeled by local (Mayo Clinic) hepatologists. How-
ever, the average body mass index in the population
rose from 2005 to 2014 but not for NAFLD patients,
suggesting that, overall, trends in clinical practice may
not be the principle drivers behind these findings. The
authors excluded all patients with other liver diseases
(e.g. viral hepatitis). The patient with cleared hepatitis
C and NAFLD, however, though excluded from this
study could experience all of the same risks as the
included subjects. For this reason, the exclusion criteria
may underestimate these trends.
This is the time to invest in efforts toward increased
awareness, early lifestyle intervention, and optimal
multidisciplinary management to identify those at
increased risk of death from liver disease as well as car-
diovascular disease. The hope, though prospective
studies are needed, is that early interventions will
reduce the risk of death from both liver disease and
cardiovascular disease. Two barriers may obstruct pro-
gress. One, though the finding of NAFLD may lead
to referral to our clinics, few hepatologists practice in a
clinical program equipped to modify cardiovascular
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FIG. 1. The central role of the hepatologist in coordinated care for NAFLD. Hepatologists are uniquely positioned in the health care
system to optimize the management of patients with NAFLD. In this conceptual diagram, we describe the resources needed and the
relationships that should be cultivated in order to enhance clinical care for patients with NAFLD.
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risk.(7) Models for multidisciplinary clinics, effective
lifestyle interventions, and efficient collaboration with
other specialists in cardiology, endocrinology, and bar-
iatric surgery are rare but needed. Two, it is not clear
whether the association between NAFLD and cardio-
vascular risk has been sufficiently disseminated in the
community. This study suggests that NAFLD is
increasing in the young and is a marker of impending
cardiovascular risk, but it is not clear whether this find-
ing is an effective trigger for intensified risk factor
management at the community level. A referral to hep-
atology may be the best opportunity to start early if we
are sufficiently prepared for those who have the pro-
gressive form of NAFLD. However, it is likely that a
minority of these patients will be seen or referred until
we study and develop a population-based screening
program for advanced fibrosis using noninvasive bio-
markers. Outreach to young, asymptomatic, well
patients with risk factors that aims to increase the
amount of care provided can be challenging. Physicians
may be unaware, patients may not be motivated, and
the system may not be prepared. Efforts to increase
awareness of and act upon these data are essential, but
without the infrastructure to address the problem, such
efforts may not deliver the desired results.
In our conceptual diagram (Fig. 1), we lay out how
hepatologists can maximize their impact for popula-
tions with and at risk for NAFLD. To address our
clinical preparedness for the expected increased volume
of referrals for NAFLD, we outline a minimum set of
clinical resources including fibrosis risk assessment
(including vibration-controlled elastography and mag-
netic resonance elastography), nutritional consultation
or detailed support through carefully selected smart-
phone apps, and, because patients are less likely to
respond to vague exhortations to increased activity,
preprepared specific recommendations for exercise.(8)
Where multidisciplinary clinics are not feasible, efforts
to cultivate steady relationships with specific clinicians
in bariatrics/endobariatrics and preventive cardiologists
or endocrinologists will serve to streamline referrals
and standardize clinical evaluation and recommenda-
tions. Finally, hepatologists must be advocates for
patients with NAFLD. This will include performing
outreach to referring clinicians and securing resources
from the hospital system for clinical support and
electronic decision supports to facilitate case finding
and linkage to care based on, for example, elevated liver
enzymes or radiographic hepatosteatosis.
Now that Allen and colleagues have shined
their spotlight on the impact of NAFLD, the next
steps are clear. We need to organize, build a team,
and fight.
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